Press Release

Antithrombin Market to Exhibit 4.1% CAGR, Rising Prevalence of Hereditary Antithrombin Deficiency to Boost Market

Antithrombin Market to Exhibit 4.1% CAGR, Rising Prevalence of Hereditary Antithrombin Deficiency to Boost Market

The rising demand reported in therapeutics segment is prognosticated to catapult it to the fore of the Global Antithrombin Market in terms of application, finds Fortune Business Insights in a new study. The study is titled “Antithrombin Market: Global Market Analysis, Insights, and Forecasts, 2018 – 2026.” According to the study, the global antithrombin market will exhibit a steady CAGR of 4.1% to reach a value of US$ 725.2 Mn by 2026 from US$ 490.4 Mn in 2018.

Request Sample [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antithrombin-market-100470

According to a study by U.S. department of Health and Human services, antithrombin deficiency is likely to affect about 1 person in every 2000 globally. The fact that antithrombin combines with heparin and can be used for treating congenital antithrombin III deficiency is expected to boost the market in the long run.

Increasing Prevalence of Hereditary Antithrombin Deficiency to Boost Market

The rising prevalence of medical conditions such as sepsis, hereditary antithrombin deficiency, disseminated intravascular coagulation (DIC), and extracorporeal membrane oxygenation (ECMO) is creating lucrative growth opportunities for the antithrombin market. Among various application types, the therapeutics segment is anticipated to lead the market with rising number of antithrombin deficiency cases. In 2018, the therapeutics segment accounted for about 95.7% of the market and is likely to continue its dominance in the future as Fortune Business Insights.

However, the high treatment cost of antithrombin may compel end users to look for cheaper alternatives or supplements. This may hamper the market globally. Again, developing countries in Asia Pacific may directly opt out of adopting antithrombin treatment because of the high price of this treatment. This may pose a challenge for market players, also hampering the overall profit percentage of the market.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/antithrombin-market-100470

Secondary Data Sources That We Refer To

  • Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market
  • Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.
  • Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, Clinics
  • Industry journals and paid databases

By Application

  • Therapeutics
  • Research
  • Diagnostics & Others

By Source

  • Human
  • Goat Milk (Recombinant)
  • Others

By Dosage Form

  • Lyophilized
  • Liquid

Strong Distribution Network Enables SCL Behring, Grifols, and Shire Expand Global Footprint

The global antithrombin market was dominated by three major companies namely SCL Behring, Grifols, and Shire. In 2018, these three companies together accounted for the highest market share among others. They offer the most commonly used human antithrombin based anticoagulants. Besides this, they have a strong distribution network that makes them have the lion’s share.

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close